More about Imatinib and Nilotinib Combination Therapy in Chronic Myeloid Leukemia

Publisher： Karger

E-ISSN： 1421-9662|129|1|18-19

ISSN： 0001-5792

Source： Acta Haematologica, Vol.129, Iss.1, 2012-09, pp. : 18-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy

By  

Acta Haematologica, Vol. 118, Iss. 3, 2007-09 ,pp. : 162-164

Karger

Access to resources Recommend Favorite

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia

By  

Case Reports in Oncology, Vol. 8, Iss. 1, 2015-03 ,pp. : 122-127

Karger

Access to resources Recommend Favorite

Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4284-4289

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination of EUTOS score and 3‐month BCR‐ABL transcript level identifies a group of good‐risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : E135-E137

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chronic Myeloid Leukemia Monitoring after Imatinib Failure: Still More Questions than Answers

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 246-247

Karger

Access to resources Recommend Favorite